KISIMA
DEAD

Serial Number

87149001

Owner

AMAL Therapeutics SA

Attorney

Jennifer Fraser

Filing Date

Aug 24, 2016

Add to watchlist:

No watchlists yet
View on USPTO

KISIMA Trademark

Serial Number: 87149001 • Registration: 5577986

KISIMA is a trademark filed by AMAL Therapeutics SA on August 24, 2016. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently no longer active.

Owner Contact Info

AMAL Therapeutics SA

c/o Fondation pour Recherches Médicales
Geneva 1205 , CH

Entity Type: 99

Trademark Details

Filing Date

August 24, 2016

Registration Date

October 9, 2018

Published for Opposition

July 24, 2018

Cancellation Date

April 25, 2025

Goods & Services

Pharmaceutical, medical and veterinary preparations, namely, proteins, peptides, and modified peptides for the treatment and prevention of tumor and cancer diseases, infectious diseases, and autoimmune diseases; proteins and derivatives of peptides and proteins as well as protein- and peptide-pools for medical purposes for the treatment and prevention of tumor and cancer diseases, infectious diseases, and autoimmune diseases; macromolecules, namely, peptides, proteins, nucleic acids and derivatives of peptides, proteins, and nucleic acids for medical and pharmaceutical purposes for the treatment and prevention of tumor and cancer diseases, infectious diseases, and autoimmune diseases; diagnostic preparations for medical and veterinary use; biological preparations, namely, proteins, peptides, modified peptides for the treatment and prevention of tumor and cancer diseases, infectious diseases, and autoimmune diseases; cells for medical purposes; pharmaceutical preparations and compositions, namely, pharmaceutical preparations and compositions for the treatment and prevention of cancer; nucleic acids, in particular recombinant nucleic acids; nucleic acids for medical purposes, namely, for the treatment and prevention of tumor and cancer diseases, infectious diseases, and autoimmune diseases; nucleic acid sequences for medical purposes, namely, for diagnostic purposes and the treatment and prevention of tumor and cancer diseases, infectious diseases, and autoimmune diseases; proteins for medical purposes, namely, for diagnostic purposes and for the treatment and prevention of tumor and cancer diseases, infectious diseases, and autoimmune diseases; macromolecules and biologically active substances for medical purposes for the treatment and prevention of tumor and cancer diseases, infectious diseases, and autoimmune diseases; kits containing preparations for medical purposes, comprised primarily of pharmaceutical preparations for the treatment and prevention of tumor and cancer diseases, and pharmaceutical preparations namely, proteins, peptides, modified peptides for the treatment and prevention of infectious diseases, and autoimmune diseases

Peptides, proteins, modified peptides and proteins and derivatives of peptides and proteins used in industry and science, in particular peptides, proteins, modified peptides and proteins and derivatives of peptides and proteins for industrial and scientific purposes, all the foregoing being chemical preparations for industrial and scientific use; biochemical products, in the nature of biochemical preparations and substances for analyses in laboratories; diagnostic preparations containing peptides, proteins, modified peptides, modified proteins, derivatives of peptides, derivatives of proteins, nucleic acids, derivatives of nucleic acids, or cells for scientific purposes; peptide substrates for scientific purposes, namely, biochemical peptide substrates for laboratory or research use; proteins for use in science, industry and manufacture; biological preparations, namely, cell cultures, tissue cultures; chemical reagents containing peptides, proteins, modified peptides, modified proteins, derivatives of peptides, derivatives of proteins, nucleic acids, derivatives of nucleic acids, or cells for scientific and research purposes and biochemical reagents containing peptides, proteins, modified peptides, modified proteins, derivatives of peptides, derivatives of proteins, nucleic acids, derivatives of nucleic acids, or cells for scientific and research purposes; nucleic acids, in particular recombinant nucleic acids; nucleic acids for scientific purposes; nucleic acid sequences; biological active peptides for scientific and research purposes; antisera for scientific and industrial purposes; all above other than for medical and veterinary use

Medical services; Veterinary services; Hygienic and beauty care for human beings or animals; Agriculture, horticulture and forestry services, namely, pest control for agriculture, horticulture and forestry, farming services in the field of grain; Pharmaceutical services, namely, pharmaceutical advice, pharmaceutical compounding services; Medical information

Scientific and technological services and research and design relating thereto, namely, scientific research, analysis and testing in the field of pharmaceuticals, medicine, biochemistry and biotechnology, and design of biochemical macromolecules, in particular proteins, peptides and nucleic acids, and biochemical preparations for scientific, medical and industrial use; Industrial analysis and research services in the field of pharmaceuticals, medicine, biochemistry and biotechnology; research and development services all relating to science; medical product and pharmaceutical research and development services; biological scientific research and development and clinical scientific research and development services; research and development services all relating to industry in the field of pharmaceuticals, medicine, biochemistry and biotechnology; research and development services all relating to biochemistry and biotechnology; research and development services all relating to products and tools to be used in biotechnical, biochemical, medical and pharmaceutical research; medical and pharmacological research services; medical research; scientific research for medical purposes; laboratory research services in the field of protein, peptide and molecular biology; provision of information and data relating to medical product and scientific research and development; medical and pharmaceutical product development and evaluation; Pharmaceutical, medical, biotechnological and biochemical research and development services for the pharmaceutical industry; Information technology services for the pharmaceutical and healthcare industries, namely, planning, design and management of information technology systems, consulting in the field of information technology, design and development of computer software

Filing History

CANCELLED SEC. 8 (6-YR)
Apr 25, 2025 C8..
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Oct 9, 2023 REM1
REGISTERED-PRINCIPAL REGISTER
Oct 9, 2018 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jul 24, 2018 NPUB
PUBLISHED FOR OPPOSITION
Jul 24, 2018 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jul 4, 2018 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Jun 20, 2018 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jun 18, 2018 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jun 18, 2018 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jun 11, 2018 TROA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Jun 11, 2018 TCCA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Dec 20, 2017 GNRN
NON-FINAL ACTION E-MAILED
Dec 20, 2017 GNRT
NON-FINAL ACTION WRITTEN
Dec 20, 2017 CNRT
TEAS/EMAIL CORRESPONDENCE ENTERED
Nov 28, 2017 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Nov 28, 2017 CRFA
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Nov 26, 2017 ERSI
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Jun 8, 2017 GNS3
LETTER OF SUSPENSION E-MAILED
Jun 8, 2017 GNSL
SUSPENSION LETTER WRITTEN
Jun 8, 2017 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
May 16, 2017 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
May 16, 2017 CRFA
ASSIGNED TO LIE
May 12, 2017 ALIE
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Apr 20, 2017 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Dec 7, 2016 GNRN
NON-FINAL ACTION E-MAILED
Dec 7, 2016 GNRT
NON-FINAL ACTION WRITTEN
Dec 7, 2016 CNRT
ASSIGNED TO EXAMINER
Dec 5, 2016 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Aug 29, 2016 NWOS
NEW APPLICATION ENTERED
Aug 27, 2016 NWAP